Michaella Alexandrou, Deniz Mutlu, Athanasios Rempakos, Ahmed Al Ogaili, James W Choi, Paul Poommipanit, Khaldoon Alaswad, Mir Babar Basir, Rhian Davies, Farouc A Jaffer, Phil Dattilo, Lorenzo Azzalini, Nazif Aygul, Niranjan Reddy, Brian K Jefferson, Sevket Gorgulu, Jaikirshan J Khatri, Laura D Young, Oleg Krestyaninov, Dmitrii Khelimskii, Jarrod Frizzell, Basem Elbarouni, Bavana V Rangan, Olga C Mastrodemos, M Nicholas Burke, Yader Sandoval, Emmanouil S Brilakis
{"title":"Ranolazine in chronic total occlusion percutaneous coronary intervention.","authors":"Michaella Alexandrou, Deniz Mutlu, Athanasios Rempakos, Ahmed Al Ogaili, James W Choi, Paul Poommipanit, Khaldoon Alaswad, Mir Babar Basir, Rhian Davies, Farouc A Jaffer, Phil Dattilo, Lorenzo Azzalini, Nazif Aygul, Niranjan Reddy, Brian K Jefferson, Sevket Gorgulu, Jaikirshan J Khatri, Laura D Young, Oleg Krestyaninov, Dmitrii Khelimskii, Jarrod Frizzell, Basem Elbarouni, Bavana V Rangan, Olga C Mastrodemos, M Nicholas Burke, Yader Sandoval, Emmanouil S Brilakis","doi":"10.25270/jic/24.00059","DOIUrl":null,"url":null,"abstract":"<p><p>Ranolazine is an anti-anginal medication given to patients with chronic angina and persistent symptoms despite medical therapy. We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).</p>","PeriodicalId":49261,"journal":{"name":"Journal of Invasive Cardiology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Invasive Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.25270/jic/24.00059","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Ranolazine is an anti-anginal medication given to patients with chronic angina and persistent symptoms despite medical therapy. We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).
期刊介绍：
The Journal of Invasive Cardiology will consider for publication suitable articles on topics pertaining to the invasive treatment of patients with cardiovascular disease.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
